Metformin treatment after the hypoxia-ischemia attenuates brain injury in newborn rats
Metrics: PDF 941 views | HTML 2505 views | ?
Mingchu Fang1, Huai Jiang1, Lixia Ye1, Chenchen Cai1, Yingying Hu1, Shulin Pan1, Peijun Li2, Jian Xiao3 and Zhenlang Lin1
1Department of Neonatology, The Second Affiliated Hospital and Yuying Children’s Hospital, Wenzhou Medical University, Wenzhou, Zhejiang 325027, China
2Center for Neuroscience Research, Children’s National Health System, Washington, DC 20010, United States
3Molecular Pharmacology Research Center, School of Pharmacy, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China
Jian Xiao, email: email@example.com
Zhenlang Lin, email: firstname.lastname@example.org
Keywords: metformin, neonatal hypoxic-ischemic brain injury, neuronal apoptosis, neuroinflammation, blood-brain barrier
Received: June 27, 2017 Accepted: July 30, 2017 Published: September 08, 2017
Neonatal hypoxic-ischemic (HI) brain injury is a devastating disease that often leads to death and detrimental neurological deficits. The present study was designed to evaluate the ability of metformin to provide neuroprotection in a model of neonatal hypoxic-ischemic brain injury and to study the associated molecular mechanisms behind these protective effects. Here, we found that metformin treatment remarkably attenuated brain infarct volumes and brain edema at 24 h after HI injury, and the neuroprotection of metformin was associated with inhibition of neuronal apoptosis, suppression of the neuroinflammation and amelioration of the blood brain barrier breakdown. Additionally, metformin treatment conferred long-term protective against brain damage at 7 d after HI injury. Our study indicates that metformin treatment protects against neonatal hypoxic-ischemic brain injury and thus has potential as a therapy for this disease.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.